Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
http://link.springer.com/content/pdf/10.1007/s10147-010-0173-3.pdf
Reference30 articles.
1. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
2. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726
3. Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944–948
4. Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791–808
5. Esteva FJ, Valero V, Booser D et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800–1808
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial;PLOS ONE;2017-06-06
2. Ultrasensitive electrochemical immunoassay of proteins based on in situ duple amplification of gold nanoparticle biolabel signals;Chemical Communications;2015
3. Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?;Cancers;2014-03-25
4. Breast Circulating Tumor Cells: Potential Biomarkers for Breast Cancer Diagnosis and Prognosis Evaluation;Omics Approaches in Breast Cancer;2014
5. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials;BMC Cancer;2013-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3